Compare Flagstar Bank NA (FLG) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs Moderna, Inc. — how do they compare? Flagstar Bank NA trades at $11.23 (market cap $4.71B), while Moderna, Inc. trades at $207.59 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 16.7× Flagstar Bank NA's market cap, and Flagstar Bank NA pays a 0.35% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Flagstar Bank NA for 21 Days and Moderna, Inc. for 59 Days on average.
| FLG | MRNA | |
|---|---|---|
Market Cap | $4.71B | $78.65B |
Volume | 7,410,589 | 37,373,437 |
Sector | Financials | Health |
52-Week High | $15.36 | $203.46 |
52-Week Low | $10.72 | $22.36 |
Typical Hold Time | 21 Days | 59 Days |
Enterprise Value | $15.25B | $74.80B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLG trades at $11.21, down 0.8% with bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with a high P/E of 378.33 but attractive P/B of 0.62, while transitioning from a $177M loss in 2025 to profitability in 2026. Recent news highlights strategic partnerships and a $250M share repurchase program, though Q2 2026 earnings missed expectations.
Analyst consensus remains bullish with a $17.07 price target (60% buy ratings), offering significant upside potential. Key risks include volatile cash flows and competitive banking pressures. The current discount to book value and institutional support suggest long-term value if profitability trends continue.
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
